Document is current
Any future updates will be listed below
-
Authors
de Kraker, Marlieke E. A.
Jackson, Holly
Hernandez Padilla, Ana Catalina
van Werkhoven, C. Henri
Francois, Bruno
-
Funding
Funding for this research was provided by:
European Union’s Horizon 2020 Research and Innovation programme (965313)
European Union’s Horizon 2020 Research and Innovation programme (965313)
European Union’s Horizon 2020 Research and Innovation programme (965313)
European Union’s Horizon 2020 Research and Innovation programme (965313)
European Union’s Horizon 2020 Research and Innovation programme (965313)
- License Information
-
More Information
Article History
Received: 5 June 2026
Accepted: 10 June 2026
First Online: 18 June 2026
<!--Emphasis Type='Bold' removed-->Declarations
:
: Data from all patients in POS-VAP were collected following the European General Data Protection Regulation and after approval of the POS-VAP protocol by the ethical committees from the participating hospitals and/or national authorities, as applicable. All clinical research has been conducted according to the principles of the Declaration of Helsinki, GCP and local legislations. For patients, ethical procedures followed standard practices for observational studies at each site/country; in most cases, signed informed consent was obtained from patients, or their legal representative. For the remainder of patients, a hospital-wide consent for data use, waiver of consent, or non-objection notice was in place.
: Not applicable.
: CHvW reports consultancy fees from MSD/Merck and Sanofi-Pasteur and research grants from MSD/Merck, LimmaTech, BioMérieux and DaVolterra. BF reports consulting fees from Astrazeneca and Aurobac. All other authors declare that they have no competing interests.
